Compugen (NASDAQ:CGEN) CEO Eran Ophir Sells 5,625 Shares

Compugen Ltd. (NASDAQ:CGEN) CEO Eran Ophir sold 5,625 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $2.21, for a total transaction of $12,431.25. Following the transaction, the chief executive officer directly owned 11,375 shares of the company’s stock, valued at approximately $25,138.75. This trade represents a 33.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Compugen Price Performance

Shares of Compugen stock opened at $2.26 on Friday. Compugen Ltd. has a 1 year low of $1.13 and a 1 year high of $2.38. The business has a 50 day moving average price of $1.96 and a 200 day moving average price of $1.77. The company has a market capitalization of $213.68 million, a P/E ratio of 6.11 and a beta of 2.77.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.55. Compugen had a return on equity of 55.68% and a net margin of 48.57%.The company had revenue of $67.33 million during the quarter, compared to the consensus estimate of $14.30 million. As a group, research analysts expect that Compugen Ltd. will post -0.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CGEN. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. HC Wainwright began coverage on shares of Compugen in a report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price target for the company. Finally, Truist Financial raised shares of Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

Hedge Funds Weigh In On Compugen

Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its holdings in shares of Compugen by 3.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after buying an additional 51,565 shares during the last quarter. State Street Corp boosted its holdings in Compugen by 3.9% in the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after acquiring an additional 14,701 shares during the last quarter. Jane Street Group LLC boosted its holdings in Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after acquiring an additional 359,785 shares during the last quarter. Two Sigma Investments LP grew its position in Compugen by 10.6% during the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 18,929 shares during the period. Finally, Marshall Wace LLP grew its position in Compugen by 135.7% during the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 61,202 shares during the period. Hedge funds and other institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.